Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-00446687 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Cohort 1; Study Period 1, 2, 3 or 4 | PLACEBO_COMPARATOR | Cohort 1: Exploring two single doses of PF-00446687 200 mg as well as sildenafil 100mg and placebo (double dummy design) |
| Cohort 2; study periods 1, 2, 3 or 4 | PLACEBO_COMPARATOR | Cohort 2: Exploring single doses of PF-00446687 20 mg - 175 mg. Subjects to receive two of 3 possible doses of PF-00446687 as well as a single dose of sildenafil 100mg and placebo (double dummy design). |
| Study period 1, 2 or 3 | EXPERIMENTAL | - |
| Placebo Study period 1, 2 or 3 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PF-00446687 | DRUG | Single 200mg dose as an oral solution |
| Placebo | DRUG | Placebo for oral solution |
| Sildenafil | DRUG | Single oral dose 100 mg tablet |
Inclusion Criteria: * Males aged 18-65 years who has given written informed consent to participate in the study and who suffers moderate to severe erectile dysfunction who has a current or recent successful response to treatment with phosphodiesterase type 5 inhibitors Exclusion Criteria: * Males...
PF-00446687 is an investigational small molecule being developed by Pfizer for the treatment of Erectile Dysfunction and Female Sexual Dysfunction. It is in Phase 2 clinical development, meaning it is not yet approved and is still being studied for safety and efficacy in these conditions.
PF-00446687 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 2 clinical trials for Erectile Dysfunction and Female Sexual Dysfunction.
PF-00446687 is in Phase 2 clinical development. It is an investigational drug, not yet approved by regulatory authorities. Two Phase 2 trials have been completed, one in post-menopausal women with Female Sexual Dysfunction and one in males with Erectile Dysfunction.
PF-00446687 has completed two Phase 2 clinical trials. NCT00479570 studied the drug in post-menopausal women with Female Sexual Dysfunction, enrolling 23 participants in Denmark, Norway, and Sweden. NCT00862888 studied the drug in males with Erectile Dysfunction, enrolling 39 participants in Norway and the United Kingdom.
PF-00446687 is a small molecule designed to treat sexual dysfunction. Its specific molecular target has not been disclosed in available information, so its exact mechanism of action is not publicly detailed. The drug is being studied for its effects on Erectile Dysfunction and Female Sexual Dysfunction.